SCHEMBL3762802

SCHEMBL3762802

COc1ccc(CCN(C)C)cc1Nc1nccc(-c2c(Cl)nc3ccccn23)n1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALK Q9UM73 3/20 0.53
CDK19 Q9BWU1 2/20 0.53
CDK2 P24941 5/20 0.49
INSR P06213 4/20 0.47
ALDH1A1 P00352 1/20 0.45
LMNA P02545 1/20 0.45
IGF1R P08069 5/20 0.44
RET P07949 3/20 0.44
PRKD3 O94806 2/20 0.44
MAP4K4 O95819 2/20 0.44
LCK P06239 2/20 0.44
FYN P06241 2/20 0.44
CSF1R P07333 2/20 0.44
MET P08581 2/20 0.44
ROS1 P08922 2/20 0.44
FLT1 P17948 2/20 0.44
KDR P35968 2/20 0.44
MAP4K2 Q12851 2/20 0.44
STK3 Q13188 2/20 0.44
TAOK1 Q7L7X3 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3760802 0.88 CDK2 (0.47) ALKCDK19CDK2INSRALDH1A1
SCHEMBL3762499 0.84 CDK19 (0.63) ALKCDK19CDK2IGF1RRET
SCHEMBL3755334 0.84 CDK19 (0.70) ALKCDK19CDK2INSRIGF1R
SCHEMBL3767846 0.83 CDK19 (0.59) ALKCDK19INSRIGF1RRET
SCHEMBL3762013 0.83 CDK2 (0.62) CDK2ALDH1A1IGF1RKDRGSK3B
SCHEMBL3757040 0.82 IGF1R (0.55) CDK2INSRIGF1RRETPRKD3
SCHEMBL3761753 0.81 CDK2 (0.52) CDK2INSRIGF1RABL1EGFR
SCHEMBL3759158 0.80 CDK2 (0.51) CDK2INSRIGF1RMAP4K4LCK
SCHEMBL3765209 0.80 CDK2 (0.52) CDK2INSRIGF1REGFRCDK4
SCHEMBL3761151 0.80 CDK2 (0.56) CDK2INSRIGF1REGFRCDK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2435436-B1 PYRIMIDINE INHIBITORS OF KINASE ACTIVITY ABBVIE INC (US) 2014-07-30 EP disclosed
US-8354422-B2 Pyrimidine inhibitors of kinase activity ABBOTT LABORATORIES INC. (US) 2013-01-15 US disclosed
WO-2010138576-A1 PYRIMIDINE INHIBITORS OF KINASE ACTIVITY ABBOTT LABORATORIES (US) 2010-12-02 WO disclosed
US-20100305126-A1 Pyrimidine Inhibitors of Kinase Activity ABBOTT LABORATORIES (US) 2010-12-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305126-A1 Pyrimidine Inhibitors of Kinase Activity IGF1R, CDK2, TK1 ALK 534/4885CDK19 53/4885CDK2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.